Investor's Business Daily on MSN

Edwards wavers analysts debate its earnings miss amid hefty TAVR investments

Edwards Lifesciences stock wavered Wednesday, though the heart-valve replacement maker issued a bullish outlook for 2026.

EW's Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs

Edwards' Q4 EPS lags estimates but revenues top as TAVR and TMTT surge. Shares rise with 2026 sales growth seen at 8%-10%.